ArticleEuropean journal of nuclear medicine and molecular imaging2024
The role of biomarkers and dosimetry parameters in overall and progression free survival prediction for patients treated with personalized
Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Artificial Intelligence Across the Cancer Theranostics Workflow: Critical Appraisal of Current Evidence and Future Clinical Translation.Molecular imaging and biology · 2026Review
- Advances in Materials for Strontium-Yttrium Separation: A Comprehensive Review.Materials (Basel, Switzerland) · 2026Review
- Deep learning-guided attenuation and scatter correction ofAnnals of nuclear medicine · 2026Article
- Evaluation of end-to-end 3D absorbed dose distribution inEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Pre-Treatment PET Radiomics for Prediction of Disease-Free Survival in Cervical Cancer.Cancers · 2025Article
- CT-free attenuation and Monte-Carlo based scatter correction-guided quantitativeEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Deep learning-based segmentation of ultra-low-dose CT images using an optimized nnU-Net model.La Radiologia medica · 2025Article
- Deep Learning-Powered CT-Less Multitracer Organ Segmentation From PET Images: A Solution for Unreliable CT Segmentation in PET/CT Imaging.Clinical nuclear medicine · 2025Article
- Potential of Radiomics, Dosiomics, and Dose Volume Histograms for Tumor Response Prediction in Hepatocellular Carcinoma followingMolecular imaging and biology · 2025Article
- Interventional oncology: A primer for clinicians on the role of ablation and embolization for solid tumors.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundOverall Survival (OS) and Progression-Free Survival (PFS) analyses are crucial metrics for evaluating the efficacy and impact of treatment. This study evaluated the role of clinical biomarkers and dosimetry parameters on survival outcomes of patients undergoing MATERIALS/
methodsThis preliminary and retrospective analysis included 17 patients with hepatocellular carcinoma (HCC) treated with
resultsThe median OS was 11 months [95% CI: 8.5, 13.09], whereas the PFS was seven months [95% CI: 5.6, 10.98]. Univariate analysis demonstrated the presence of Ascites (HR: 9.2[1.8,47]) and the aim of SIRT (segmentectomy, lobectomy, palliative) (HR: 0.066 [0.0057, 0.78]), Aspartate aminotransferase (AST) level (HR:0.1 [0.012-0.86]), and MAA-Dose-V
conclusionThis preliminary study confirmed the role played by baseline clinical biomarkers and dosimetry parameters in predicting the treatment outcome, paving the way for the establishment of a dose-effect relationship. In addition, the feasibility of using ML along with these features was demonstrated as a helpful tool in the clinical management of patients, both prior to and following
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.